TTOO Price to Sales Ratio vs Cost of Revenue Analysis
TTOO Stock | USD 3.05 0.19 6.64% |
T2 Biosystms financial indicator trend analysis is much more than just breaking down T2 Biosystms prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether T2 Biosystms is a good investment. Please check the relationship between T2 Biosystms Price To Sales Ratio and its Cost Of Revenue accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in T2 Biosystms. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.
Price To Sales Ratio vs Cost Of Revenue
Price to Sales Ratio vs Cost of Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of T2 Biosystms Price to Sales Ratio account and Cost of Revenue. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between T2 Biosystms' Price to Sales Ratio and Cost of Revenue is -0.12. Overlapping area represents the amount of variation of Price to Sales Ratio that can explain the historical movement of Cost of Revenue in the same time period over historical financial statements of T2 Biosystms, assuming nothing else is changed. The correlation between historical values of T2 Biosystms' Price to Sales Ratio and Cost of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price to Sales Ratio of T2 Biosystms are associated (or correlated) with its Cost of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost of Revenue has no effect on the direction of Price to Sales Ratio i.e., T2 Biosystms' Price to Sales Ratio and Cost of Revenue go up and down completely randomly.
Correlation Coefficient | -0.12 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Price To Sales Ratio
Price to Sales Ratio is figured by comparing T2 Biosystms stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on T2 Biosystms sales, a figure that is much harder to manipulate than other T2 Biosystms multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period.Cost Of Revenue
Cost of Revenue is found on T2 Biosystms income statement and represents the costs associated with goods and services T2 Biosystms provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most indicators from T2 Biosystms' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into T2 Biosystms current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in T2 Biosystms. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.As of the 28th of March 2024, Selling General Administrative is likely to drop to about 26 M. In addition to that, Issuance Of Capital Stock is likely to drop to about 45 M
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 6.6M | 6.1M | 5.7M | 5.0M | Depreciation And Amortization | 318K | 39K | 35.1K | 33.3K |
T2 Biosystms fundamental ratios Correlations
Click cells to compare fundamentals
T2 Biosystms Account Relationship Matchups
High Positive Relationship
High Negative Relationship
T2 Biosystms fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 28.5M | 79.1M | 60.5M | 34.4M | 39.5M | 62.0M | |
Short Long Term Debt Total | 44.8M | 55.8M | 57.1M | 59.2M | 68.1M | 40.9M | |
Other Current Liab | 13.6M | 6.4M | 7.2M | 7.7M | 8.8M | 6.6M | |
Total Current Liabilities | 60.6M | 9.8M | 11.7M | 10.5M | 12.1M | 23.0M | |
Total Stockholder Equity | (34.0M) | 8.7M | (12.9M) | (40.0M) | (46.0M) | (43.7M) | |
Other Liab | 46K | 4.8M | 4.6M | 4.9M | 5.6M | 5.9M | |
Property Plant And Equipment Net | 9.2M | 14.8M | 14.4M | 13.3M | 15.3M | 9.8M | |
Net Debt | 33.7M | 39.0M | 34.9M | 48.9M | 56.2M | 59.0M | |
Retained Earnings | (376.2M) | (423.0M) | (472.2M) | (534.5M) | (481.1M) | (457.0M) | |
Accounts Payable | 3.8M | 2.1M | 2.8M | 1.3M | 1.5M | 1.6M | |
Cash | 11.0M | 16.8M | 22.2M | 10.3M | 9.3M | 8.8M | |
Non Current Assets Total | 9.6M | 25.5M | 16.1M | 15.0M | 17.2M | 11.7M | |
Cash And Short Term Investments | 11.0M | 42.2M | 32.2M | 10.3M | 9.3M | 8.8M | |
Common Stock Total Equity | 36K | 44K | 51K | 147K | 169.1K | 177.5K | |
Common Stock Shares Outstanding | 455.1K | 24.3K | 31.8K | 51.0K | 58.7K | 55.7K | |
Liabilities And Stockholders Equity | 28.5M | 79.1M | 60.5M | 34.4M | 39.5M | 62.0M | |
Non Current Liabilities Total | 1.9M | 60.6M | 61.8M | 63.9M | 57.5M | 34.1M | |
Other Current Assets | 1.4M | 2.7M | 3.1M | 2.6M | 3.0M | 1.5M | |
Other Stockholder Equity | 342.1M | 431.5M | 459.2M | 494.6M | 568.7M | 288.0M | |
Total Liab | 62.5M | 70.4M | 73.4M | 74.4M | 66.9M | 50.8M | |
Property Plant And Equipment Gross | 9.2M | 14.8M | 14.4M | 13.3M | 15.3M | 9.8M | |
Total Current Assets | 18.9M | 53.6M | 44.4M | 19.4M | 17.5M | 16.6M | |
Accumulated Other Comprehensive Income | (11.3M) | (13.2M) | 9K | (4K) | (3.6K) | (3.8K) | |
Short Term Debt | 42.9M | 1.2M | 1.2M | 1.4M | 1.6M | 1.5M | |
Common Stock | 49K | 147K | 166K | 8K | 9.2K | 8.7K | |
Property Plant Equipment | 5.8M | 14.8M | 14.4M | 13.3M | 15.3M | 9.5M | |
Net Tangible Assets | (32.1M) | 8.7M | (12.9M) | (40.0M) | (36.0M) | (34.2M) | |
Current Deferred Revenue | 285K | 230K | 518K | 172K | 154.8K | 147.1K | |
Net Receivables | 2.8M | 5.1M | 5.1M | 2.2M | 2.5M | 2.2M | |
Retained Earnings Total Equity | (266.1M) | (317.2M) | (376.2M) | (423.0M) | (380.7M) | (399.7M) | |
Capital Surpluse | 267.4M | 328.5M | 342.1M | 431.5M | 496.3M | 308.8M | |
Inventory | 3.6M | 3.6M | 3.9M | 4.3M | 5.0M | 2.6M | |
Capital Lease Obligations | 3.9M | 10.5M | 9.4M | 9.6M | 11.0M | 5.7M |
Currently Active Assets on Macroaxis
When determining whether T2 Biosystms offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of T2 Biosystms' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of T2 Biosystms Stock. Outlined below are crucial reports that will aid in making a well-informed decision on T2 Biosystms Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in T2 Biosystms. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for TTOO Stock analysis
When running T2 Biosystms' price analysis, check to measure T2 Biosystms' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy T2 Biosystms is operating at the current time. Most of T2 Biosystms' value examination focuses on studying past and present price action to predict the probability of T2 Biosystms' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move T2 Biosystms' price. Additionally, you may evaluate how the addition of T2 Biosystms to your portfolios can decrease your overall portfolio volatility.
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |
Is T2 Biosystms' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of T2 Biosystms. If investors know TTOO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about T2 Biosystms listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (35.62) | Revenue Per Share 7.933 | Quarterly Revenue Growth (0.60) | Return On Assets (0.68) | Return On Equity (6.22) |
The market value of T2 Biosystms is measured differently than its book value, which is the value of TTOO that is recorded on the company's balance sheet. Investors also form their own opinion of T2 Biosystms' value that differs from its market value or its book value, called intrinsic value, which is T2 Biosystms' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because T2 Biosystms' market value can be influenced by many factors that don't directly affect T2 Biosystms' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between T2 Biosystms' value and its price as these two are different measures arrived at by different means. Investors typically determine if T2 Biosystms is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, T2 Biosystms' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.